Recombinant adenoviral vector containing HCV NS4 antigen can induce both cellular and humoral immune responses.

The dose and route of immunization have significant impact on the induction of antigen specific immune responses.

Very high or low doses of immunization with recombinant adenovectors do not induce optimum immunity.

The induction of neutralizing antibodies is dependent upon route of immunization.

Dose and route of immunization must be carefully selected when using adenovectors based vaccine candidates.